Format

Send to

Choose Destination
Regul Toxicol Pharmacol. 2009 Nov;55(2):111-22. doi: 10.1016/j.yrtph.2009.05.019. Epub 2009 Jun 13.

Health risk assessment procedures for endocrine disrupting compounds within different regulatory frameworks in the European Union.

Author information

1
Karolinska Institutet, Institute of Environmental Medicine, 171 77 Stockholm, Sweden. anna.beronius@ki.se

Abstract

In this study we have investigated how different regulatory frameworks in Europe cope with identification and risk assessment of endocrine disrupting compounds (EDCs). Four regulatory groups were selected for the investigation: existing industrial chemicals, environmental pollutants in food, pharmaceuticals and plant protection products. The legislation and guidelines for each of these groups were scrutinized and compared in detail. In addition, one recent European risk assessment document each for three identified EDCs, i.e. bisphenol A, dioxins and vinclozolin, were reviewed and compared. We found that the requirements for toxicity testing and availability and scope of risk assessment guidelines varied between the four regulatory frameworks. Also, the general principles regarding the human relevance of the mode of action identified in animal tests differed in the different risk assessments. In conclusion, there is little conformity in the risk assessment processes between these groups of chemicals. Because of the complicated nature of endocrine disruption, test methods, principles and criteria for data interpretation traditionally used might not be directly applicable to EDCs and further development of a transparent and reliable risk assessment process for this type of substances is needed.

PMID:
19500631
DOI:
10.1016/j.yrtph.2009.05.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center